Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2025; 21
DOI: 10.1055/s-0045-1807788
BREAST TUMORS
1928
POSTER PRESENTATION

Real-world validation of outcomes with adjuvant paclitaxel + trastuzumab (APT) in low-risk early-stage HER2 positive breast cancer

Authors

  • Christopher Lucas Negrete

  • Rafael Duarte Paes

  • Aline Coelho Gonçalves

  • Rafael Brant Costa

  • Flavia Rocha Paes

  • Daniel Gimenes

  • Luciana Castro Garcia Landeiro

  • Cristiano Augusto Andrade de Resende

  • Leandro Jonata de Carvalho Oliveira

  • Bruno Lemos Ferrari

  • Pedro Emanuel Rubini Liedke

  • Max Senna Mano

  • Rodrigo Dienstmann

Further Information
  All articles of this category

Keywords

HER2-positive breast cancer - APT protocol - real world data (RWD)


Publication History

Article published online:
06 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Christopher Lucas Negrete, Rafael Duarte Paes, Aline Coelho Gonçalves, Rafael Brant Costa, Flavia Rocha Paes, Daniel Gimenes, Luciana Castro Garcia Landeiro, Cristiano Augusto Andrade de Resende, Leandro Jonata de Carvalho Oliveira, Bruno Lemos Ferrari, Pedro Emanuel Rubini Liedke, Max Senna Mano, Rodrigo Dienstmann. Real-world validation of outcomes with adjuvant paclitaxel + trastuzumab (APT) in low-risk early-stage HER2 positive breast cancer. Brazilian Journal of Oncology 2025; 21.
DOI: 10.1055/s-0045-1807788